CCN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Crit Care Nurse 2004 Aug; 24(4): 54-61

This Article
Right arrow Full Text (PDF)
Right arrow Respond to This Article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Take the CE Test
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perozzi, K. J.
Right arrow Articles by Englert, N. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perozzi, K. J.
Right arrow Articles by Englert, N. C.


High-Risk Obstetrics
CE Online

Amniotic Fluid Embolism

An Obstetric Emergency

Katherine J. Perozzi, RN, MSN
Nadine C. Englert, RN, MSN


Katherine J. Perozzi was the undergraduate perinatal nursing coordinator and a lecturer at the University of Pittsburgh School of Nursing, Pittsburgh, Pa, when this article was written. She is now an assistant professor at the School of Nursing and Allied Health at Robert Morris University in Moon Township, Pa. She has 17 years of experience in obstetric nursing.

Nadine C. Englert is the primary teacher and manager of the nursing skills laboratory at the University of Pittsburgh School of Nursing, Pittsburgh, Pa. She has 13 years of experience in medical-surgical and critical care nursing.

To purchase reprints, contact The InnoVision Group, 101 Columbia, Aliso Viejo, CA 92656. Phone, (800) 809-2273 or (949) 362-2050 (ext 532); fax, (949) 362-2049; e-mail, reprints{at}aacn.org.

To receive CE credit for this article, visit the American Association of Critical-Care Nurses’ (AACN) Web site at http://www.aacn.org, click on "Education" and select "Continuing Education," or call AACN’s Fax on Demand at (800) 222-6329 and request item No. 1192.


Although the first reported case of amniotic fluid embolism (AFE) was documented in 1926,1 a historic event that received much public and medical attention predates that case by more than 100 years. Public records indicate that in 1817 an obstetrician named Sir Richard Croft was widely criticized because of the unexpected death of one of his patients and her unborn son. The patient was Princess Charlotte of Wales, and the condemnation and grief Croft experienced because of this loss apparently led him to commit suicide. Investigations, continuing at least until the 1970s, strongly suggest that the princess died of AFE, possibly absolving Sir Richard of mismanagement of a difficult labor and highlighting a senseless third tragedy.2

Even today, AFE is the leading cause of death during labor and the first few postpartum hours,3 and it remains a deadly and unpreventable obstetric emergency.4 Despite technological advances in critical care life support, the maternal mortality rate for AFE remains around 61%; a large percentage of survivors have permanent hypoxia-induced neurological damage. The fetal mortality rate, although better than the maternal rate, is a dismal 21%, and 50% of the surviving neonates experience permanent neurological injury.5

Description and Etiology

Normally, amniotic fluid does not enter the maternal circulation because it is contained safely within the uterus, sealed off by the amniotic sac. AFE occurs when the barrier between amniotic fluid and maternal circulation is broken and, possibly under a pressure gradient, fluid abnormally enters the maternal venous system via the endocervical veins, the placental site (if placenta is separated), or a uterine trauma site.6 Why this entry into maternal circulation occurs in some women and not in others is not clearly understood. The devastating consequence of circulating fetal debris (carried by amniotic fluid) occurs only rarely, even though during normal labor and delivery, cesarean deliveries, and minor traumatic procedures fetal tissue may pass into maternal circulation and cause no symptoms.7 That AFE develops in only a minute proportion of these women suggests that either it is an effect of the amount of exposure to fetal debris or the type of fetal debris (containing meconium or not) or that some maternal factors may play a significant role.5,8 Clark et al5 contend that AFE more closely resembles an anaphylactic reaction to fetal debris than an embolic event, and they propose the term "anaphylactoid syndrome of pregnancy" instead of AFE. The exact mechanism of this anaphylactoid reaction to amniotic fluid is not clearly understood.

Predisposing factors once considered to be associated with AFE include placental abruption, uterine overdistention, fetal death, trauma, tumultuous or oxytocin-stimulated labor, multiparity, advanced maternal age, and rupture of membranes.4 However, in numerous documented cases of AFE, none of these conditions or demographic characteristics occurred or were applicable at the time of the event. Furthermore, a recent analysis of 46 verified cases of AFE did not substantiate most of these as associated factors; 12% of the cases occurred in women with intact membranes, 70% during labor, 11% after vaginal delivery, and 19% during cesarean delivery with or without labor.5

Incidence and Inclusion Criteria

The reported incidence of AFE varies widely because of the obscurity of the problem and the wide range of signs and symptoms associated with it. According to Gilbert and Danielsen,9 AFE occurs in 1 of every 20646 deliveries. Thanks to increasing awareness of the syndrome, this number is probably more accurate than many earlier estimates, which ranged from 1 in 8000 to 1 in 80000. Precise reporting of incidence is extremely difficult because no definitive clinical or laboratory test is available that can be used to provide an exclusive diagnosis of AFE or completely rule it out. Clark and coworkers established a national registry for AFE in an effort to investigate and understand this syndrome more completely. Table 1Go lists the inclusion criteria for diagnosis of AFE.


View this table:
[in this window]
[in a new window]
 
Table 1 National registry’s criteria for diagnosis of amniotic fluid embolism 5,10

 
Clinical Features and Pathophysiology

One of the major factors that makes AFE so devastating is its total unpredictability. Although most cases occur after the onset of labor, some incidents have occurred outside of labor. As mentioned earlier, several clinical conditions seem to be associated with AFE, but essentially there are no definitive clues, warning signs, or associated conditions that indicate the risk of AFE may be increased. Most experts agree that AFE, as it is known now, cannot be predicted or prevented.11

According to Gei and Hankins,11 the initial signs and symptoms have a typical chronology, and the morbidity and mortality of the manifestations steadily decreases with time. Most often, respiratory distress and cyanosis occur suddenly within the first minute and are quickly followed by hypotension, pulmonary edema, shock, and neurological manifestations such as confusion, loss of consciousness, and seizures. More than 80% of patients experience cardiorespiratory arrest within the first few minutes.6 Approximately 50% of patients do not survive this onslaught of cardiopulmonary injury, but of those who do, 40% to 50% have coagulopathy and hemorrhage up to 4 hours later.12 Porter et al13 noted that in some patients, coagulopathy may be the first indication of AFE, whereas Clark et al5 reported that seizure activity may at times be the first manifestation.

The pathophysiology of AFE is speculative; various theories have been published. Gei and Hankins11 proposed a pathophysiological course (see FigureGo). Three distinct responses or a combination of clinical responses to circulating fetal debris are suggested.



View larger version (65K):
[in this window]
[in a new window]
 
 
The initial respiratory reaction possibly begins with transient pulmonary vasospasm.14 Although this possible transient vasospasm has not been documented (probably because the signs and symptoms appear so abruptly in a seemingly healthy person who is not being monitored via invasive methods), vasospasm may be caused by amniotic microemboli that trigger the release of arachidonic acid metabolites15 and lead to pulmonary hypertension, intrapulmonary shunting, bronchoconstriction, and severe hypoxia.14 Exactly which components of amniotic fluid actually cause this effect is unknown, but Clark14 suggests that abnormal components such as meconium may play a role. Many experts16–22 speculate that maternal mediators also may have an influence.

The second manifestation includes negative inotropism and left ventricular failure resulting in increasing pulmonary edema and hypotension quickly leading to shock. The third manifestation is a neurological response to the respiratory and hemodynamic injury, which may include seizures, confusion, or coma.11

About 40% to 50% of patients who survive to this point have severe coagulopathy, usually disseminated intravascular coagulation, which results in uncontrollable uterine bleeding along with bleeding from puncture sites such as insertion sites for intravenous and epidural catheters.11 This coagulopathy is thought to be precipitated by several procoagulant components of amniotic fluid, most notably thromboplastin, which initiate the extrinsic pathway of the clotting cascade and result in excessive fibrinolytic activity.8,11,23,24

Possibly before the onset of maternal signs and symptoms, but most certainly as they appear, initial changes in fetal heart rate patterns become evident on the electronic fetal monitor. These changes are due to decreased uterine perfusion and the resultant decreased placental blood flow associated with maternal hypotension.11 Fetal reserve necessary to compensate for this decreased perfusion is quickly depleted, and the fetus shows signs of hypoxia-induced distress. The normal fetal heart rate is from 110/min to 160/min with moderate short-term variability of 6/min to 25/min. (Short-term variability is defined as the difference between successive heartbeats as measured by the R-R interval of the QRS cardiac cycle and is reliably assessed only via internal fetal monitoring. Short-term variability gives the fetal heart rate tracing a zigzag appearance on the monitor strip.) A decrease in fetal oxygenation, in this situation due to maternal hypotension and hypoxia, can rapidly lead to the appearance of nonreassuring patterns in fetal heart rate (Table 2Go).


View this table:
[in this window]
[in a new window]
 
Table 2 Possible changes in fetal heart rate patterns associated with fetal hypoxia25–27

 
Correction of the cause of these changes, that is, maternal hypotension and hypoxia, is the only remedy. Therefore, resuscitation of the mother and stabilization of her condition are the priorities. When fetal heart rate is being assessed, the appearance of nonreassuring patterns should be viewed in the context of the overall clinical picture. Each of the patterns listed in Table 2Go may have more than a single cause; some of the causes are relatively benign and easily correctable. For example, simply changing the mother’s position, providing her with fluids for volume expansion, and/or initiating oxygen supplementation may improve matters. However, the seriousness of AFE is quickly made evident by the rapid deterioration in fetal status and the apparent futility of measures normally implemented to improve it.

Diagnosis

Immediate recognition and diagnosis of AFE is essential to improve maternal and fetal outcomes. Until recently, the diagnosis of AFE was made only after an autopsy of the mother revealed squamous cells, lanugo hair, or other fetal and amniotic material in the pulmonary arterial vasculature.11,28 Although laboratory data may indicate that AFE is likely, as noted previously, no single laboratory or clinical finding can be used to diagnose or exclude it.6,7 Diagnosis, therefore, must be based on clinical features, and AFE should not be confused with other pregnancy-related complications or medical conditions (Table 3Go). Obstetric nurses and critical care nurses caring for obstetric patients should familiarize themselves with this condition, as Gei and Hankins11 imply that an increased awareness of this syndrome has resulted in earlier diagnosis, aggressive intervention, and probably a better chance of survival.


View this table:
[in this window]
[in a new window]
 
Table 3 Differential diagnosis of amniotic fluid embolism

 
Management

Once the signs and symptoms are recognized and a presumptive diagnosis is made, supportive measures should be implemented promptly. In the event of cardiac arrest, the resuscitation team should follow standard Advanced Cardiac Life Support protocols for obstetric patients.23 Ideally, overall management of AFE should take place in an obstetric intensive care unit. Many hospitals lack obstetric intensive care units and so the patient must be cared for in a medical or surgical intensive care unit. Critical care nurses without obstetric expertise often become anxious when caring for pregnant patients; however, the initial principles of dealing with obstetric emergencies are the same as for any emergency: airway, breathing, and circulation. The major difference for this particular emergency is the need to care for 2 patients.

The fetus should be monitored continuously for signs of compromise (preferably by an obstetric nurse with expertise in electronic fetal monitoring). Specific to pregnant women is the importance of positioning. In order to ensure optimal uterine perfusion throughout the management of AFE, the mother’s hips should be displaced to the left to prevent the weight of the gravid uterus from compressing the inferior vena cava and compromising blood flow.29

Oxygenation

The fetus is very vulnerable to maternal hypoxia,28 which is initially profound in AFE. Therefore, the first priority is resuscitation of the mother4 and administration of oxygen by any means available at concentrations of 100%.7,24

A more aggressive approach includes securing an airway through endotracheal intubation, providing mechanical ventilation for the patient with a high inspired fraction of oxygen (>60%), and the addition of positive end-expiratory pressure.6,7,11 Positive end-expiratory pressure is typically started at 5 cm H2O and increased by increments of 2 to 3 cm H2O until satisfactory levels of PaO2 are reached.11 The goal of oxygen therapy is to maintain arterial PaO2 higher than 60 mm Hg and arterial oxygen saturation at 90% or higher.6,24,30

Circulation

Maintaining cardiac output and blood pressure involves several simultaneous interventions. Gei and Hankins11 recommend positioning the patient flat or in a slight Trendelen-burg position to improve the venous blood return and perfusion of the central nervous system. Supportive measures include the initiation of fluid therapy, administration of pharmacological agents (Table 4Go), and electrocardiographic monitoring to detect and treat arrhythmias; most patients with AFE initially have electromechanical dissociation or bradycardia.5 Placement of a pulmonary artery catheter is highly recommended for monitoring cardiac output, central venous pressure, and pulmonary artery pressures (Table 5Go). In addition, pulmonary artery catheters provide direct access for blood samples to be sent for cytological analysis for amniotic fluid and fetal debris.36


View this table:
[in this window]
[in a new window]
 
Table 4 Pharmacological support in amniotic fluid embolism31–33

 

View this table:
[in this window]
[in a new window]
 
Table 5 Hemodynamic monitoring34,35

 
Volume replacement with isotonic crystalloid solution is a first-line therapy for maintaining blood pressure.24 Fluid therapy should be based on the findings of central venous monitoring, so as to avoid overhydration in these patients, who are predisposed to pulmonary edema.6 Therapy for left ventricular dysfunction should be directed toward improving inotropy.37 Gillie and Hughes32 recommend several inotropic agents as drugs of choice for maintaining cardiac output and blood pressure (Table 4Go). A clinical guideline for supporting critically ill obstetric patients is to maintain systolic blood pressure at or higher than 90 mm Hg,24 with acceptable organ perfusion, as indicated by a urine output of 25 mL/h or more.30

Control of Hemorrhage and Coagulopathy

The results of hematologic studies can be used to diagnose and monitor the course of bleeding and disseminated intravascular coagulation.7 According to Martin et al,23 control of uterine bleeding can often be accomplished with uterine massage and the administration of pharmacological agents (Table 4Go). If bleeding is profuse and pharmacological intervention is unsuccessful, a hysterectomy may be necessary.

Administration of blood transfusions and blood components is considered the first line of treatment for correcting coagulopathy associated with AFE.6 Blood products include packed red blood cells, fresh-frozen plasma, platelets, and cryoprecipitate to maintain organ perfusion and urinary output until bleeding due to disseminated intravascular coagulation resolves.30 Cryoprecipitate is particularly useful in AFE because it can be used to replenish clotting factors in lieu of fresh-frozen plasma in volume-restricted patients. In addition, cryoprecipitate contains both fibrinogen and fibronectin, which facilitate the removal of cellular and particulate matter (eg, amniotic fluid debris) from the blood via the reticuloendothelial system.6 McCance and Huether38 explain that the reticuloendothelial system, now referred to as the mononuclear phagocyte system, consists of a line of cells that ingest and destroy (by phagocytosis) unwanted materials in the blood.

Another pharmacological intervention is the use of intravenous steroids. Amniotic fluid not only displaces blood and reduces oxygen and waste exchange but also introduces antigens, cells, and protein aggregates that trigger inflammation within the bloodstream.39 In consideration of the potential inflammatory response and similarities to anaphylaxis, the administration of corticosteroids (Table 4Go) may be helpful in AFE.5,11,24

In summary, the 3 main goals of treatment are (1) oxygenation, (2) maintaining cardiac output and blood pressure, and (3) correcting coagulopathy. Intensive care nurses, including those without obstetric training, are expected to learn the critical assessment-management actions beginning with the primary and secondary surveys of critically ill patients. Once the mother’s condition is stabilized, the focus of attention is fetal delivery.

Fetal Considerations

In some instances, and of course most favorable for the fetus, AFE does not occur until after delivery. When AFE occurs before or during delivery, however, the fetus is in grave danger from the onset because of the maternal cardiopulmonary crisis. In addition to concern for fetal well-being, delivery of the fetus increases the chances for a good outcome for the mother because the weight of the gravid uterus on the inferior vena cava impedes blood return to the heart and decreases systemic blood pressure.23,40 Therefore, as soon as the mother’s condition is stabilized, delivery of the viable infant should be expedited. If resuscitation of the mother is futile, an emergency bedside cesarean delivery may be necessary to save the infant. Undeniably, the sooner after maternal cardiopulmonary arrest that the fetus is delivered, the more favorable is the fetal outcome.5,41 Therefore, as difficult as it may be, and even though the mother may be viewed as the primary patient, prolonged resuscitation efforts should be discouraged.

Family Support

Because the maternal and fetal mortality rates are so high, most likely an intensive care nurse will be called on to support the patient’s family members through crisis and/or loss. When the mother and infant are gravely ill, keeping their family members well informed and allowing as much access to the loved ones as possible are important. Warren42 reported that accessibility to physicians, unrestricted visits, and caring conveyance of adequate information were important to families’ satisfaction with the intensive care unit experience. When possible, providing and encouraging contact and interaction between parents and the newborn are essential in promoting parent-infant attachment.

In many cases, the mother dies but the infant survives. It is important to understand that an event that was anticipated with much hope and joy has gone terribly awry and that validating the wide range of emotions that the family might experience can facilitate grieving. In addition, the stages of normal grieving, anger and blame, can interfere with the normal parent-infant attachment and decrease the frequency of nurturing behaviors. Referral to counseling and support groups is most often helpful.

When both the mother and the infant die, it is important to allow the father and other family members time with their deceased loved ones. Staff members should be present to facilitate the initial contact and to answer questions, but they should also allow families to be alone. Pictures of the infant should be taken and offered to the family for keeping. Any infant clothing or blankets used, as well as infant identification bands, should be saved and given to the family. Many obstetric units have special "memory boxes" specifically for this purpose.

Summary

AFE is an unpredictable, unpreventable, and, for the most part, an untreatable obstetric emergency. Management of this condition includes prompt recognition of the signs and symptoms, aggressive resuscitation efforts, and supportive therapy. Any delays in diagnosis and treatment can result in increased maternal and/or fetal impairment or death. Whereas once the invariable outcome of AFE was death of the mother, today the prognosis is somewhat brighter thanks to increased awareness of the syndrome and advances in intensive care medicine. In any case, intensive care nurses are called on to provide physical, lifesaving care to the patient and her fetus. Both during and after the event, supportive care must be administered to the patient’s family members, who are dealing with crisis and loss.

References

  1. Meyer JR. Embolus pulmonarcaseosa. Braz J Med Biol Res. 1926;2:301–303.
  2. Humphrey A. Princess of Wales: a royal tragedy. Midwives Chron. 1989;102:304–305.[Medline]
  3. Gogola J, Hankins GDV. Amniotic fluid embolism in progress: a management dilemma. Am J Perinatol. 1998;8:491–493.
  4. Sisson MC. Amniotic fluid embolism. Crit Care Obstet. 1992;4:667–673.
  5. Clark SL, Hankins GDV, Dudley DA, Dildy GA, Porter TF. Amniotic fluid embolism: analysis of the national registry. Am J Obstet Gynecol. 1995;172:1158–1169.[Medline]
  6. Bastien JL, Graves JR, Bailey S. Atypical presentation of amniotic fluid embolism. Anesth Analg. 1998;87:124–126.[Free Full Text]
  7. Thomson AJ, Greer IA. Non-haemorrhagic obstetric shock. Ballieres Best Pract Res Clin Obstet Gynaecol. 2000;14:19–41.
  8. Lewis PS, Lanouette JM. Principles of critical care. In: Cohen WR, ed. Cherry and Merkatz Complications of Pregnancy. 5th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000:763–771.
  9. Gilbert MG, Danielsen B. Amniotic fluid embolism: decreased mortality in a population-based study. Obstet Gynecol. 1999;93: 973–977.[Abstract/Free Full Text]
  10. Park EH, Sachs BP. Postpartum hemorrhage and other problems of the third stage. In: James DR, Steer PJ, Weiner CP, Gonik B, eds. High Risk Pregnancy: Management Options. 2nd ed. Philadelphia, Pa: WB Saunders Co; 2000:1231–1246.
  11. Gei G, Hankins GDV. Amniotic fluid embolism: an update. Contemp Ob/Gyn. January 2000;45:53–66.
  12. Weiner CP. The obstetric patient and disseminated intravascular coagulation. Clin Perinatol. 1986;13:705–717.[Medline]
  13. Porter TF, Clark SL, Dildy GA, Hankins GA. Isolated disseminated intravascular coagulation and amniotic fluid embolism [abstract]. Am J Obstet Gynecol. 1996;174:486.
  14. Clark SL. New concepts of amniotic fluid embolism: a review. Obstet Gynecol Surv. 1990;45:360–368.[Medline]
  15. Reeves WC, Demers LM, Wood MA, et al. The release of thromboxane A2 and prostacyclin following experimental acute pulmonary embolism. Prostaglandins Leukot Med. 1983;11:1–10.[Medline]
  16. Oi H, Kobayashi H, Hirashima Y, et al. Serological and immunohistochemical diagnosis of amniotic fluid embolism. Semin Thromb Hemost. 1998;24:479–484.[Medline]
  17. Hammerschidt DE, Ogburn PL, Williams JE. Amniotic fluid activates complement: a role in amniotic fluid embolism syndrome? J Lab Clin Med. 1984;104:901–907.[Medline]
  18. Azegami M, Mori N. Amniotic fluid embolism and leukotrienes. Am J Obstet Gynecol. 1986;155:1119–1124.[Medline]
  19. Lee HC, Yamaguchi M, Ikenoue T, et al. Amniotic fluid embolism and leukotrienes: the role of amniotic fluid surfactant in leukotriene production. Prostaglandins Leukot Essent Fatty Acids. 1992;47:117–121.[Medline]
  20. El Maradny E, Kanayama N, Halim A, et al. Endothelin has a role in early pathogenesis of amniotic fluid embolism. Gynecol Obstet Invest. 1995;40:14–18.[Medline]
  21. Lunetta P, Penttila A. Immunohistochemical identification of syncytiotrophoblastic cells and megakaryocytes in pulmonary vessels in a fatal case of amniotic fluid embolism. Int J Legal Med. 1996;108:210–214.[Medline]
  22. Fineschi V, Gambassi R, Gherardi M, et al. The diagnosis of amniotic fluid embolism: an immunohistochemical study for the quantification of pulmonary mast cell tryptase. Int J Legal Med. 1998;111:238–243.[Medline]
  23. Martin PS, Leaton MB. Emergency: amniotic fluid embolism [published correction appears in Am J Nurs. May 2001;101:14]. Am J Nurs. March 2001;101:43–44.
  24. Locksmith GJ. Amniotic fluid embolism. Obstet Gynecol Clin North Am. 1999;26: 435–444.[Medline]
  25. Menihan CA, Zottoli EK. Electronic Fetal Monitoring: Concepts and Applications. Philadelphia, Pa: Lippincott; 2000:27–63.
  26. Olds SB, London ML, Ladewig PA. Maternal-Newborn Nursing: A Family and Community-Based Approach. 6th ed. Upper Saddle River, NJ: Prentice Hall Health; 2001:524–534.
  27. Parer J. Fetal heart rate. In: Creasy RK, Resnik R, eds. Maternal-Fetal Medicine. 4th ed. Philadelphia, Pa: WB Saunders Co; 1999:270–299.
  28. Chamberlain G, Steer P. ABC of labour care: obstetric emergencies. BMJ. 1999; 318:1342–1345.[Free Full Text]
  29. Dudney TM, Elliott CG. Pulmonary embolism from amniotic fluid, fat, and air. Prog Cardiovasc Dis. 1994;35:447–474.
  30. Hankins GDV, Clark SL. Amniotic fluid embolism. Fetal Matern Med Rev. 1997; 9:35–47.
  31. Dildy GA. Postpartum hemorrhage: new management options. Clin Obstet Gynecol. 2002;45:330–344.[Medline]
  32. Gillie MH, Hughes SC. Amniotic fluid embolism. Anesthesiol Clin North Am. 1993;11:55–76.
  33. Spratto GR, Woods AL. PDR Nurse’s Drug Handbook. Motvale, NJ: Delmar; 1998.
  34. Dvorak-King C. PA catheter numbers made easy. RN. November 1997;60:45–49.
  35. Cardiac output measurement. In: Moreau D, ed. Handbook of Nursing Procedures. Springhouse, Pa: Schilling-McCann; 2001.
  36. Rizk NW, Kalassian KG, Gilligan T, Druzin MI, Daniel DL. Obstetric complications in pulmonary and critical care medicine. Chest. 1996;110:791–809.[Free Full Text]
  37. Benson KT. Diagnosis and treatment of amniotic fluid embolism. Anesthesiol Rev. 1994;21:47–52.
  38. McCance KL, Huether SE. The hematologic system. In: Pathophysiology: The Biologic Basis for Disease in Adults and Children. St Louis, Mo: Mosby; 1998:845–877.
  39. McCance KL, Huether SE. The cardiovascular and lymphatic systems. In: Pathophysiology: The Biologic Basis for Disease in Adults and Children. St Louis, Mo: Mosby; 1998:1024–1092.
  40. Martin RW. Amniotic fluid embolism. Clin Obstet Gynecol. 1996;39:101–106.[Medline]
  41. Katz VJ, Dotters DJ, Droegemueller W. Perimortem cesarean delivery. Obstet Gynecol. 1986;68:571–576.[Abstract/Free Full Text]
  42. Warren NA. Critical care family members’ satisfaction with bereavement experiences. Crit Care Nurs Q. August 2002;25:54–60.[Medline]




This Article
Right arrow Full Text (PDF)
Right arrow Respond to This Article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Take the CE Test
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perozzi, K. J.
Right arrow Articles by Englert, N. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perozzi, K. J.
Right arrow Articles by Englert, N. C.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS